Legal Challenge Could Put UK Drug Pricing Deal At Risk
Executive Summary
The body representing generics and biosimilars companies in the UK is seeking a seat at the table as negotiations on a new voluntary price scheme get under way.
You may also be interested in...
UK In Major Move To Boost Commercial Clinical Trials & Improve Life Sciences Environment
The publication of two major reports has led the UK government to announce a £650m “Life Sci for Growth” package to bolster the life sciences sector.
BGMA Lines Up New Leadership With Change Of Vice-Chair
UK generics and biosimilars industry association the BGMA is laying the groundwork for new leadership after appointing Sandoz UK head Diane DiGangi Trench as its vice-chair, ahead of her moving up to chair next year.
UK Generics Body Opens Rift With Government And Originators Over Rebate Scheme
By launching a bid for judicial review of its exclusion from UK negotiations over the VPAS rebate scheme, the BGMA has thrust itself into conflict with the country’s government as well as local brand industry association the ABPI.